Engineering a new CAR-T for solid tumours
Our high impact publication in the Journal of Clinical Investigation explores a protein called STEAP2 that is highly expressed on prostate cancer cells but is traditionally challenging to target. Building on our experience in antibody discovery and protein engineering, our scientists succeeded in isolating STEAP2-targeting antibodies and developed a novel, armoured CAR-T that can withstand the hostile microenvironment of solid tumours.
Find out more about the potential of this STEAP2-targeted CAR-T in solid tumours and our ongoing work to bring next generation therapies to more patients living with cancer globally.
https://www.jci.org/articles/view/169655
------------------------------------------------------------
Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/
Follow us:
Twitter: / astrazeneca
LinkedIn: / astrazeneca
Instagram: / astrazeneca
Facebook: / astrazeneca